Support Alert

NHS England Clinical Policy: puberty suppressing hormones

NHS England has issued a commissioning position: Puberty suppressing hormones (PSH) are not available as a routine commissioning treatment option for treatment of children and young people who have gender incongruence/gender dysphoria. NHS England has concluded that there is not enough evidence to support the safety or clinical effectiveness of PSH to make the treatment routinely available at this time. The clinical policy and evidence review and other documents can be found on the NHS England website.

The General Pharmaceutical Council (GPhC) has published a news story advising pharmacy teams to take account of relevant national and local policies and guidance, alongside their standards and guidance. The news story can be found on the GPhC website.

Pharmacists that have further questions or would like to discuss this with a peer, can contact the RPS Professional Support team.


Email newsletter

Want the latest pharmacy news and updates straight to your inbox?

Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.

Sign Up